Central Asia Metals plc (CAMLF)

OTC Markets OTCPK: CAMLF · 실시간 가격 · USD

2.75

+0.00 (0.00%)

종가 기준: Sep 04, 2026, 8:00 PM

알림

Alert

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

데이터 없음

매수호가	2
시가총액	469M
매출 (ttm)	276M
순이익 (ttm)	-45.7M
	1.21
	-0.25
	n/a
	n/a
P/B (ttm)	1.60
P/S (ttm)	1.70
실적 발표일	n/a

매도호가	2.65
거래량	300
평균 거래량 (20일)	2,857
시가	2.47
전일 종가	2.75
일중 범위	2.47 - 2.47
52주 범위	1.68 - 3.59
애널리스트	n/a
목표주가	n/a
배당	$0.21 (7.57%)
배당락일	Sep 24, 2026

CAMLF 소개

Central Asia Metals plc, together with its subsidiaries, operates as a base metals producer. The company produces copper, zinc, silver, and lead minerals. It also owns a 100% interest in the Kounrad solvent extraction-electrowinning operation located near the city of Balkhash in central Kazakhstan; and in the Sasa mine located in north Macedonia. Central Asia Metals plc was incorporated in 2005 and is headquartered in London, the United Kingdom....

[더 보기]

산업 Copper

섹터 Basic Materials

IPO 일자 Sep 3, 2021

직원 수 717

상장 거래소 OTC Markets OTCPK

티커 CAMLF

웹사이트 https://www.centralasiametals.com

전체 기업 정보

재무 실적

2025년 Central Asia Metals plc의 매출은 229.86M로, 전년 214.44M 대비 7.19% 증가했습니다. 순이익은 -75.05M로, -246.03% 감소했습니다.

재무제표

어닝 서프라이즈

Central Asia Metals plc가 Invalid Date에 분기 실적을 발표했습니다:

매출 n/a 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS 예상치 하회 , 및 NaN% 전년 대비 성장.

주가가 움직인 이유

뉴스

1주 전 · GuruFocus.com

Central Asia Metals PLC (CAMLF) (H1 2026) Earnings Call Highlights: Record EBITDA and Strategic ...

Central Asia Metals PLC (CAMLF) reports a 89% surge in EBITDA to $75.5 million, driven by strong commodity prices and operational improvements, while advancing its growth pipeline.

1주 전 · Proactive

Central Asia Metals CEO: 'Really positive' H1 as Cygnus deal and drill assays loom

Central Asia Metals PLC (AIM:CAML, OTC:CAMLF) CEO Gavin Ferrar spoke with Proactive's Stephen Gunnion about the company's strong first-half 2026 performance, the proposed acquisition of Cygnus Metals,...

1주 전 · Proactive

Faron Pharmaceuticals, Central Asia Metals, Gelion, S&U, Mila Resources, Georgina Energy

Faron Pharmaceuticals Limited (AIM:FARN) is set to start its phase IIb BEXERA trial for blood cancer drug bexmarilimab in the second half of this year. It'll test the drug in 90 patients across the US...

1주 전 · Proactive

Central Asia Metals says revenue jumped 46% boosted by higher prices and higher volumes

Central Asia Metals PLC (AIM:CAML, OTC:CAMLF) shares climbed close to 10% in Wednesday's trade after it nearly doubled first-half earnings (EBITDA) and lifted its interim dividend to 8p as higher copp...

2개월 전 · Simply Wall St.

Central Asia Metals (AIM:CAML) Stock Fair Value Falls After Analyst Downgrade

Central Asia Metals is under fresh scrutiny after the stock’s fair value estimate was revised from £2.20 to £1.82, a change of about 17% that reshapes how some investors may look at its potential. Ana...

2 페이지 중 1

Central Asia Metals plc (CAMLF)